# Question 18

**Type:** Clinical Data

**Question:** What are the most frequently administered systemic therapy regimens for lung cancer patients in the MSK-CHORD Study?

**Answer:**

## Summary: Most Frequently Administered Systemic Therapy Regimens for Lung Cancer Patients in MSK-CHORD

Based on the MSK-CHORD study (MSK, Nature 2024) data, which includes **7,809 non-small cell lung cancer (NSCLC) patients**, with **6,111 patients receiving systemic therapy** (28,923 total treatment administrations):

### **Top Single Agents:**

1. **Pemetrexed** - 3,768 administrations (3,347 patients)
2. **Carboplatin** - 3,724 administrations (3,371 patients)
3. **Pembrolizumab** - 1,729 administrations (1,569 patients)
4. **Osimertinib** - 1,345 administrations (1,074 patients)
5. **Cisplatin** - 1,263 administrations (1,228 patients)
6. **Bevacizumab** - 1,203 administrations (1,036 patients)
7. **Gemcitabine** - 1,160 administrations (1,110 patients)
8. **Docetaxel** - 858 administrations (830 patients)
9. **Paclitaxel** - 817 administrations (785 patients)
10. **Erlotinib** - 808 administrations (489 patients)

### **Top Combination Regimens:**

1. **Carboplatin + Pemetrexed** - 1,210 administrations (1,176 patients)
2. **Cisplatin + Pemetrexed** - 688 administrations (680 patients)
3. **Carboplatin + Pembrolizumab + Pemetrexed** - 631 administrations (624 patients)
4. **Bevacizumab + Carboplatin + Pemetrexed** - 452 administrations (444 patients)
5. **Carboplatin + Paclitaxel** - 439 administrations (427 patients)
6. **Docetaxel + Ramucirumab** - 312 administrations (309 patients)
7. **Gemcitabine + Vinorelbine** - 311 administrations (306 patients)
8. **Bevacizumab + Cisplatin + Pemetrexed** - 157 administrations (157 patients)
9. **Carboplatin + Etoposide** - 154 administrations (142 patients)
10. **Ipilimumab + Nivolumab** - 132 administrations (128 patients)

### **Key Observations:**

- **Platinum-based chemotherapy** (carboplatin/cisplatin + pemetrexed) remains the most common first-line regimen
- **Immunotherapy** is increasingly used, with pembrolizumab being the most common checkpoint inhibitor
- **Targeted therapies** like osimertinib (EGFR inhibitor), erlotinib, crizotinib, and alectinib are frequently used
- **Combination immunotherapy + chemotherapy** regimens (e.g., carboplatin + pembrolizumab + pemetrexed) are common modern approaches

---

## Model Information
- **agent_type**: mcp-clickhouse
- **model**: anthropic:claude-sonnet-4-5-20250929
- **use_ollama**: False
- **ollama_base_url**: http://localhost:11434
- **max_tokens**: 4096

---

*Generated on 2026-02-05 01:41:03*